BMRN vs FDMT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMRN Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioMarin Pharmaceuticals Inc (BMRN) driven by superior Valuation, Growth & Margin while FDMT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, BMRN trades at 9.1x Forward P/E with 16.3% operating margin (+32.0% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, BMRN sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BMRN Revenue | FDMT Revenue | BMRN Op. Margin | FDMT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $1.49B | N/A | -8.3% | N/A | BMRN |
| FY2019 | $1.70B | $10M | -5.9% | -729.4% | BMRN |
| FY2020 | $1.86B | $10M | -2.3% | -424.0% | BMRN |
| FY2021 | $1.85B | $20M | -4.5% | -395.5% | BMRN |
| FY2022 | $2.10B | $0M | 7.7% | -3516.5% | BMRN |
| FY2023 | $2.42B | $20M | 7.7% | -544.6% | BMRN |
| FY2024 | $2.85B | $0M | 17.0% | -507678.4% | BMRN |
| FY2025 | $3.22B | $90M | 12.7% | -187.2% | BMRN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BMRN | FDMT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $11.0B | $669.3M | Larger Scale | BMRN |
| Trailing P/E Ratio Valuation | 8.8x | N/M | Lower Multiple | BMRN |
| Forward P/E Ratio Valuation | 9.1x | N/M | Lower Multiple | BMRN |
| Revenue Growth (YoY) Growth | +32.0% | +4505.6% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | 16.3% | -222.7% | Higher Margin | BMRN |
| Net Profit Margin Profitability | -0.5% | -208.6% | Higher Margin | BMRN |
| Return on Equity (ROE) Capital Efficiency | -0.3% | -56.7% | Higher ROE | BMRN |
| 52-Week Range Position Momentum | 42% ($49โ$71) | 47% ($7โ$17) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 0.28ฮฒ ยท 31% Vol | 1.89ฮฒ ยท 90% Vol | Lower Realized Risk | BMRN |
| Unified Institutional Score Composite Signal | 52.6 / 100 (HOLD) | 51.3 / 100 (HOLD) | Higher Composite | BMRN |